Nuveen LLC Buys New Position in Disc Medicine, Inc. $IRON

Nuveen LLC purchased a new position in Disc Medicine, Inc. (NASDAQ:IRON) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 112,717 shares of the company’s stock, valued at approximately $5,595,000. Nuveen LLC owned approximately 0.33% of Disc Medicine as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also added to or reduced their stakes in IRON. Janus Henderson Group PLC boosted its holdings in Disc Medicine by 62.4% in the fourth quarter. Janus Henderson Group PLC now owns 1,217,815 shares of the company’s stock worth $77,170,000 after acquiring an additional 467,988 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Disc Medicine by 23.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,394,637 shares of the company’s stock worth $88,421,000 after acquiring an additional 262,690 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Disc Medicine by 22.2% in the first quarter. Vanguard Group Inc. now owns 1,305,046 shares of the company’s stock worth $64,782,000 after acquiring an additional 236,800 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Disc Medicine by 160.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 139,720 shares of the company’s stock worth $8,856,000 after acquiring an additional 86,154 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. bought a new position in Disc Medicine in the fourth quarter worth approximately $5,147,000. Institutional investors own 83.70% of the company’s stock.

Disc Medicine Stock Performance

Shares of Disc Medicine stock opened at $59.41 on Tuesday. The company has a market cap of $2.07 billion, a PE ratio of -13.29 and a beta of 0.77. Disc Medicine, Inc. has a 52 week low of $30.82 and a 52 week high of $68.73. The business has a 50 day moving average price of $57.01 and a 200-day moving average price of $51.66. The company has a quick ratio of 32.11, a current ratio of 32.11 and a debt-to-equity ratio of 0.05.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($1.58) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.41). Equities analysts anticipate that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on IRON shares. Wedbush reiterated an “outperform” rating and issued a $90.00 price target on shares of Disc Medicine in a report on Monday, July 21st. Truist Financial initiated coverage on Disc Medicine in a report on Monday, July 21st. They issued a “buy” rating and a $86.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $118.00 price objective on shares of Disc Medicine in a research note on Thursday, July 3rd. BMO Capital Markets increased their price objective on Disc Medicine from $112.00 to $120.00 and gave the stock an “outperform” rating in a research note on Monday, May 12th. Finally, Morgan Stanley increased their price objective on Disc Medicine from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Monday, August 18th. One investment analyst has rated the stock with a Strong Buy rating and ten have issued a Buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $98.30.

Insider Activity at Disc Medicine

In related news, CEO John D. Quisel sold 34,800 shares of the stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $55.33, for a total transaction of $1,925,484.00. Following the completion of the sale, the chief executive officer directly owned 161,828 shares of the company’s stock, valued at approximately $8,953,943.24. This trade represents a 17.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Jean M. Franchi sold 2,031 shares of the stock in a transaction that occurred on Thursday, July 17th. The shares were sold at an average price of $59.00, for a total value of $119,829.00. Following the sale, the chief financial officer directly owned 63,499 shares of the company’s stock, valued at $3,746,441. The trade was a 3.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 133,622 shares of company stock valued at $7,866,795. 3.64% of the stock is owned by insiders.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.